Keywords : Monoclonal Antibody, hematology
About This Report This analysis examines the historical and projected performance for Chugai in the prescription pharmaceutical segment . The report includes global corporate vision and strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year revenue projections for key drugs. What's Included in This Report? * Get detailed data into Chugai's strategic vision across t...
More »
Search ReportLinker
The Largest Collection of Market Research Reports
» 1.2 Million Industry Reports
» 450,000 Company Profiles
» 850,000 Market Briefings
» 40,000 Country Guides
From +200,000 authoritative sources
- Publication date: November 2010
- Report price: $ 5 700
About This Report
This analysis examines the historical and projected performance for Chugai in the prescription pharmaceutical segment . The report includes global corporate vision and strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year revenue projections for key drugs.
What's Included in This Report?
* Get detailed data into Chugai's strategic vision across the next 6 years
* Analyze firm revenue projections by product, therapy area, lifecycle stage, geography, molecule type and source
Key Market Facts
Strategic insight into the prospects for Chugai over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the firm 's prescription pharmaceuticals outlook using a variety of cuts of the historical and projection sales.
Why Should You Buy This Report?
* Compare Chugai's performance against key competitors in the prescription pharmaceutical segment
* Assess the strong sales performance of the firm 's monoclonal antibody (MAb) franchise, positioning Chugai as the leading Japanese MAb player
In Vitro Diagnostic Industry in Japan
Summary
Main Facts
Prescription pharmaceutical sales and growth rate performance, 2003–15
Financial performance, 2003–15
Chugai: PharmaVitae projections at a glance
Strategic insight
[Missing title]
Chugai dominates the Japanese MAb landscape
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
ABOUT THIS PROFILE
PharmaVitae Explorer database
Chapter structure
Quarterly news update
Firms Introduction
Firms sales
Firms financials
Key products and competitors
Data sourcing
Analyst consensus
QUARTERLY NEWS UPDATE
Latest prescription pharma product news
Q1 2010
Q4 2009
Q3 2009
Q2 2009
Q1 2009
COMPANY Introduction
Main Facts
Background
Key corporate developments
Merger and Acquisition history
Consolidation into the Roche group in October 2002
Divestments since the Roche merger have promoted prescription pharmaceuticals focus
Current company organisation
COMPANY REVENUES
Main Facts
Prescription pharmaceutical sales and growth rate analysis, 2003–15
Portfolio overview
Portfolio overview, 2003–09
Portfolio overview, 2009–15
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Explanation of launch/core/expiry analysis
New Product Analysis, 2009–15
Core analysis, 2009–15
Expiry analysis, 2009–15
Launch/core/expiry configuration, 2009–15
Molecule type analysis
Externalization analysis
COMPANY FINANCIALS
Main Facts
Reconciliation between PharmaVitae-formatted prescription pharma sales and firm -reported total sales, 2003–09
Operating costs and profit analysis
Operating costs and profit analysis, 2003–09
Operating cost ratio and profit margin analysis, 2003–09
Operating cost ratio and profit margin analysis, 2009–15
Operating costs and profit analysis, 2008–14
KEY PRODUCTS AND COMPETITORS
Main Facts
Overview
Oncology
[Missing title]
Herceptin
Rituxan
Neutrogin
Tarceva
Hematology
Epogin
R-744/Mircera
Immunology & inflammation
[Missing title]
Infectious disease
Tamiflu
Pegasys
Genitourinary
Evista
APPENDIX
References
Abbreviations
Exchange rates
In Vitro Diagnostic in Japan
- $ 250
- Industry data
- January 2013
Yearly, From 2002 To 2011
By Business Monitor International
Source: United Nations Comtrade Database DESA/UNSD, BMI
- Industries : In Vitro Diagnostic
- Countries : Japan
- $ 250
- Industry data
- January 2013
Yearly, From 2002 To 2011
By Business Monitor International
Source: United Nations Comtrade Database DESA/UNSD, BMI
- Industries : In Vitro Diagnostic
- Countries : Japan
- Publication date: November 2010
- Report price: $ 5 700